About Lexicon Pharmaceuticals, Inc.
https://www.lexpharma.comLexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products.
CEO
Michael S. Exton
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2015-05-21 | Reverse | 1:7 |
ETFs Holding This Stock
Summary
Showing Top 3 of 18
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Citigroup
Buy
Piper Sandler
Overweight
Leerink Partners
Market Perform
Needham
Hold
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
ARTAL GROUP S.A.
Shares:136.18M
Value:$168.86M
SIREN, L.L.C.
Shares:38.92M
Value:$48.26M
FMR LLC
Shares:38.68M
Value:$47.96M
Summary
Showing Top 3 of 158
About Lexicon Pharmaceuticals, Inc.
https://www.lexpharma.comLexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $14.18M ▼ | $26.36M ▲ | $-12.77M ▼ | -90.04% ▼ | $-0.04 ▼ | $-10.46M ▼ |
| Q2-2025 | $28.87M ▲ | $24.92M ▼ | $3.25M ▲ | 11.27% ▲ | $0.01 ▲ | $5.75M ▲ |
| Q1-2025 | $1.26M ▼ | $26.91M ▼ | $-25.3M ▲ | -2K% ▼ | $-0.07 ▲ | $-23.28M ▼ |
| Q4-2024 | $26.55M ▲ | $33.36M ▼ | $-33.77M ▲ | -127.16% ▲ | $-0.09 ▲ | $-20.31M ▲ |
| Q3-2024 | $1.75M | $65.37M | $-64.81M | -3.7K% | $-0.18 | $-60.12M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $115.95M ▼ | $205.93M ▼ | $85.77M ▼ | $120.16M ▼ |
| Q2-2025 | $139.01M ▼ | $225.58M ▼ | $96.14M ▼ | $129.44M ▲ |
| Q1-2025 | $194.84M ▼ | $297.67M ▼ | $174.64M ▲ | $123.03M ▼ |
| Q4-2024 | $237.96M ▼ | $298.42M ▼ | $152.47M ▲ | $145.95M ▼ |
| Q3-2024 | $258.37M | $321.12M | $142.61M | $178.51M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-12.77M ▼ | $0 ▼ | $0 ▼ | $0 ▲ | $28.29M ▲ | $0 ▼ |
| Q2-2025 | $3.25M ▲ | $16.99M ▲ | $15.48M ▼ | $-45M ▼ | $-12.52M ▼ | $16.99M ▲ |
| Q1-2025 | $-25.3M ▲ | $-43.78M ▼ | $40.58M ▼ | $-572K ▼ | $-3.77M ▼ | $-43.78M ▼ |
| Q4-2024 | $-33.77M ▲ | $-21.49M ▲ | $53.7M ▲ | $-104K ▲ | $32.1M ▲ | $-21.96M ▲ |
| Q3-2024 | $-64.81M | $-53.62M | $53.47M | $-916K | $-1.07M | $-53.93M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|
 License | $0 ▲ | $30.00M ▲ | $10.00M ▼ |
 Product | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Michael S. Exton
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2015-05-21 | Reverse | 1:7 |
ETFs Holding This Stock
Summary
Showing Top 3 of 18
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Citigroup
Buy
Piper Sandler
Overweight
Leerink Partners
Market Perform
Needham
Hold
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
ARTAL GROUP S.A.
Shares:136.18M
Value:$168.86M
SIREN, L.L.C.
Shares:38.92M
Value:$48.26M
FMR LLC
Shares:38.68M
Value:$47.96M
Summary
Showing Top 3 of 158